110 related articles for article (PubMed ID: 10460008)
1. Effect of 22-oxa-1,25-dihydroxyvitamin D3 on human thyroid cancer cell growth.
Okano K; Usa T; Ohtsuru A; Tsukazaki T; Miyazaki Y; Yonekura A; Namba H; Shindoh H; Yamashita S
Endocr J; 1999 Apr; 46(2):243-52. PubMed ID: 10460008
[TBL] [Abstract][Full Text] [Related]
2. Correlation between suppression of c-myc and antiproliferative effect of transforming growth factor-beta 1 in thyroid carcinoma cell growth.
Usa T; Tsukazaki T; Namba H; Ohtsuru A; Kimura H; Villadolid MC; Nagataki S; Yamashita S
Endocrinology; 1994 Oct; 135(4):1378-84. PubMed ID: 7925100
[TBL] [Abstract][Full Text] [Related]
3. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 inhibits human thyroid carcinoma cell growth.
Kimura H; Yamashita S; Namba H; Tominaga T; Tsuruta M; Yokoyama N; Izumi M; Nagataki S
J Clin Endocrinol Metab; 1992 Aug; 75(2):596-602. PubMed ID: 1322431
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; van den Bemd GJ; Dorssers LC; Birkenhäger JC; van Leeuwen JP
Cancer Res; 1994 Nov; 54(21):5711-7. PubMed ID: 7923220
[TBL] [Abstract][Full Text] [Related]
6. Antineoplastic activity of 1,25(OH)2D3 and its analogue 22-oxacalcitriol against human anaplastic thyroid carcinoma cell lines in vitro.
Suzuki S; Takenoshita S; Furukawa H; Tsuchiya A
Int J Mol Med; 1999 Dec; 4(6):611-4. PubMed ID: 10567671
[TBL] [Abstract][Full Text] [Related]
7. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
8. Effects of two new vitamin D3 derivatives, 22-oxa-1 alpha-25-dihydroxyvitamin D3 (OCT) and 2 beta-(3-hydroxypropoxy)-1 alpha, 25-dihydroxyvitamin D3 (ED-71), on bone metabolism in organ culture.
Sato K; Nishii Y; Woodiel FN; Raisz LG
Bone; 1993; 14(1):47-51. PubMed ID: 8443002
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines.
Kawa S; Yoshizawa K; Tokoo M; Imai H; Oguchi H; Kiyosawa K; Homma T; Nikaido T; Furihata K
Gastroenterology; 1996 May; 110(5):1605-13. PubMed ID: 8613068
[TBL] [Abstract][Full Text] [Related]
10. 22-Oxacalcitriol: dissection of 1,25(OH)2D3 receptor-mediated and Ca2+ entry-stimulating pathways.
Farach-Carson MC; Abe J; Nishii Y; Khoury R; Wright GC; Norman AW
Am J Physiol; 1993 Nov; 265(5 Pt 2):F705-11. PubMed ID: 8238551
[TBL] [Abstract][Full Text] [Related]
11. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cell growth, c-myc mRNA, and 1,25-(OH)2 vitamin D3 receptor in C3H/10T1/2 mouse embryo fibroblasts by calcipotriol and 1,25-(OH)2 vitamin D3.
Trydal T; Lillehaug JR; Aksnes L; Aarskog D
Acta Endocrinol (Copenh); 1992 Jan; 126(1):75-9. PubMed ID: 1310564
[TBL] [Abstract][Full Text] [Related]
13. 1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia.
Jung SJ; Lee YY; Pakkala S; de Vos S; Elstner E; Norman AW; Green J; Uskokovic M; Koeffler HP
Leuk Res; 1994 Jun; 18(6):453-63. PubMed ID: 8207963
[TBL] [Abstract][Full Text] [Related]
14. Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression.
Sebag M; Henderson J; Rhim J; Kremer R
J Biol Chem; 1992 Jun; 267(17):12162-7. PubMed ID: 1318311
[TBL] [Abstract][Full Text] [Related]
15. 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected T cells.
Inoue D; Matsumoto T; Ogata E; Ikeda K
J Biol Chem; 1993 Aug; 268(22):16730-6. PubMed ID: 8393873
[TBL] [Abstract][Full Text] [Related]
16. 1,25-Dihydroxy vitamin D3 inhibits the Ras-MEK-ERK pathway and regulates proliferation and apoptosis of papillary thyroid carcinoma.
Li B; Lv L; Li W
Steroids; 2020 Jul; 159():108585. PubMed ID: 31982425
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; Birkenhäger JC; van Leeuwen JP
Eur J Cancer; 1996 May; 32A(5):842-8. PubMed ID: 9081364
[TBL] [Abstract][Full Text] [Related]
18. Novel vitamin D3 derivatives, 26-homo-delta 22-dehydro-1 alpha,25(S)-dihydroxyvitamin D3 and 26-homo-delta 22-dehydro-1 alpha,25(R)-dihydroxyvitamin D3: preferential activity in c-myc mRNA production and in induction of phenotypic differentiation of HL-60 cells.
Koizumi T; Nakao Y; Ishizuka S; Oshida J; Hara N; Ikekawa N; Fijita T
Arch Biochem Biophys; 1990 Feb; 276(2):310-6. PubMed ID: 2407190
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase.
Roy S; Martel J; Tenenhouse HS
J Bone Miner Res; 1995 Dec; 10(12):1951-9. PubMed ID: 8619376
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of 1,25-dihydroxyvitamin D3 stimulated osteocalcin gene transcription by tumor necrosis factor-alpha: structural determinants within the vitamin D response element.
Kuno H; Kurian SM; Hendy GN; White J; deLuca HF; Evans CO; Nanes MS
Endocrinology; 1994 Jun; 134(6):2524-31. PubMed ID: 8194478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
